Company Reports Revenue Decline, Raises 2026 Guidance
What happened
The company reported total revenue of $381.4 million, a 5% decrease compared to the previous year, primarily due to lower ELEVIDYS sales volumes. Net Product Revenue fell 13% year over year, attributed to the ambulatory-only label for ELEVIDYS. Despite this, the company raised its 2026 revenue guidance to $1.25 billion to $1.30 billion, and narrowed its 2026 expense guidance to $800 million to $825 million. Non-GAAP Operating Income reached $22.9 million, improving from a non-GAAP operating loss of $35.7 million in the third quarter of 2025.
From aol.com
Why it matters
The financial results indicate a shift in revenue streams, with PMO Franchise Revenue supported by increasing new patient enrollments. The improvement in operating income and the raised revenue guidance suggest confidence in future performance despite current sales pressures.
From aol.com
Who's involved
- James RichardsonChief Medical Officer, who was appointed on November 6, 2026
- Hoffmann-La RocheSwiss healthcare company that provided a $40 million milestone payment to James Richardson
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BlackstoneSpeculative
Blackstone might see changes in valuation due to the reported shifts in revenue.
Keep exploring
The entities involved
-
James Richardson
American musician
Nothing else this week.